Crystalline vs. Ionic Liquid Salt Forms of Active Pharmaceutical Ingredients: A Position Paper
- 2.6k Downloads
Why not consider liquid salt forms of active pharmaceutical ingredients (APIs) as an alternative versatile tool in the pharmaceutical industry? Recent developments have shown that known APIs can be readily converted into ionic liquids and that these novel phases often possess different properties (e.g., improved solubilities and dissolution rates), which may have a direct impact on the pharmacokinetics and pharmacodynamics of the drug. They may also offer the potential of novel and more efficient delivery modes, as well as patent protection for each of the new forms of the drug. Since these pharmaceutically active ionic liquids represent a thermodynamically stable phase, they avoid the troublesome issues surrounding polymorphism and “polymorphic transformation.” In some cases, an active cation and an active anion can be combined to produce a liquid possessing dual functionality. Here we examine and challenge the current industry reliance on crystalline APIs by discussing the breadth and potential impact of liquid salts as a possible approach to phase control.
KEY WORDSactive pharmaceutical ingredient delivery modes ionic liquid polymorphism salt
DRM is grateful to the Australian Research Council for his Federation Fellowship.
- 1.Heinrich Stahl P, Wermuth CG, editors. Handbook of Pharmaceutical Salts; Properties, Selection, and Use, VHCA and Wiley-VCH, 2008.Google Scholar
- 4.Byrn SR, Pfeiffer RR, Stephenson G. Solid-State Chemistry of Dugs, Inc. West Lafayette: SSCI; 1999.Google Scholar
- 13.Apotex wins latest round in generic Paxil litigation. http://www.nature.com/nrd/journal/v3/n6/full/nrd1423.html, (accessed 27/08/2009) 2004.
- 14.Draper P. Eutectic liquid drug formulation, (Can.). US: Application; 2007. p. 5.Google Scholar
- 17.Endres F, MacFarlane D, Abbott A, Editors. Electrodeposition from Ionic Liquids. Wiley-VCH, 2008.Google Scholar
- 22.Fujita K, MacFarlane DR, Forsyth M. Protein solubilising and stabilising ionic liquids. Chem Commun. 2005;4804–6.Google Scholar
- 23.Von Hagen J, Michelsen U. Use of ionic liquids for protein extraction, (Merck Patent G.m.b.H., Germany). DE: Application; 2006. p. 12.Google Scholar
- 34.Rogers RD, Seddon KR. Ionic liquids: industrial applications to green chemistry. American Chemical Society. 2003.Google Scholar
- 35.Goho A. The crystal form of a drug can be the secret to its success, 2004. www.sciencenews.org/articles/20040821/bob9.asp (accessed 27/08/2009).
- 37.Borka L, Haleblian JK. Crystal polymorphism of pharmaceuticals. Acta Pharm Jugosl. 1990;40:71–94.Google Scholar
- 41.O'Neil MJ, Smith A, Heckelman PE. The Merck Index. Whitehouse Station, NJ: Merck & Co. Inc.; 2001.Google Scholar
- 48.Fraser KJ, Izgorodina EI, Forsyth M, Scott JL, MacFarlane DR. Liquids intermediate between “molecular” and “ionic” liquids: Liquid Ion Pairs? Chem Commun. 2007;3817–9.Google Scholar
- 50.Hamamoto H, Miwa Y. Tape preparation comprising etodolac in ionic liquid form, (Medrx Co., Ltd., Japan). WO: Application; 2009. p. 35Google Scholar
- 55.Ogihara W, Kosukegawa H, Ohno H. Proton-conducting ionic liquids based upon multivalent anions and alkylimidazolium cations. Chem Commun. 2006;3637–9.Google Scholar
- 57.Stoimenovski J, MacFarlane DR. Pharmaceutically active protic ionic liquids, congress on ionic liquids 3. Australia: Cairns; 2009.Google Scholar
- 61.Bica K, Rogers RD. Confused ions in ionic liquids—pharmaceutically active ionic liquids composed of oligomers, Congress on Ionic Liquids 3, Cairns, Australia; 2009Google Scholar